首页 > 最新文献

Lancet Hiv最新文献

英文 中文
US exit would leave global HIV response with a void to fill.
IF 12.8 1区 医学 Q1 IMMUNOLOGY Pub Date : 2025-03-01 Epub Date: 2025-02-12 DOI: 10.1016/S2352-3018(25)00038-4
The Lancet Hiv
{"title":"US exit would leave global HIV response with a void to fill.","authors":"The Lancet Hiv","doi":"10.1016/S2352-3018(25)00038-4","DOIUrl":"10.1016/S2352-3018(25)00038-4","url":null,"abstract":"","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":" ","pages":"e163"},"PeriodicalIF":12.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143426523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The treatment optimisation ODYSSEY for children with HIV.
IF 12.8 1区 医学 Q1 IMMUNOLOGY Pub Date : 2025-03-01 Epub Date: 2025-02-17 DOI: 10.1016/S2352-3018(25)00033-5
George K Siberry, Theodore Ruel
{"title":"The treatment optimisation ODYSSEY for children with HIV.","authors":"George K Siberry, Theodore Ruel","doi":"10.1016/S2352-3018(25)00033-5","DOIUrl":"10.1016/S2352-3018(25)00033-5","url":null,"abstract":"","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":" ","pages":"e166-e168"},"PeriodicalIF":12.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143469587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study.
IF 12.8 1区 医学 Q1 IMMUNOLOGY Pub Date : 2025-03-01 DOI: 10.1016/S2352-3018(24)00344-8
Carolyn Bolton Moore, Kristin Baltrusaitis, Brookie M Best, John H Moye, Ellen Townley, Avy Violari, Barbara Heckman, Sarah Buisson, Rodica M Van Solingen-Ristea, Edmund V Capparelli, Mark A Marzinke, Elizabeth D Lowenthal, Shawn Ward, Chelsea Krotje, Ryan Milligan, Allison L Agwu, Jenny Huang, S Y Amy Cheung, Cynthia McCoig, Dwight E Yin, Gilly Roberts, Herta Crauwels, Veerle Van Eygen, Sara Zabih, Gaerolwe Masheto, Pradthana Ounchanum, Linda Aurpibul, Violet Korutaro, Aditya H Gaur
<p><strong>Background: </strong>Long-acting cabotegravir and long-acting rilpivirine constitute a completely intramuscular antiretroviral therapy (ART) regimen for adults with HIV. We aimed to assess the safety, antiviral activity, and pharmacokinetics of oral cabotegravir and rilpivirine followed by a combination of long-acting cabotegravir and long-acting rilpivirine in virologically suppressed adolescents with HIV.</p><p><strong>Methods: </strong>The IMPAACT 2017/MOCHA study is a phase 1/2, multicentre, open-label, non-comparative, dose-finding trial being conducted at 18 sites across Botswana, South Africa, Thailand, Uganda, and the USA. In cohort 2 of this study, adolescents (aged 12-18 years; weight ≥35 kg) with HIV and no serious comorbidities who were receiving stable combination ART with confirmed virological suppression and had either previously enrolled in the first cohort or had not previously participated in the study were eligible for inclusion. Participants stopped their background combination ART and received oral cabotegravir 30 mg once daily and oral rilpivirine 25 mg once daily orally for 4-6 weeks, followed by long-acting injectable cabotegravir 600 mg (3 mL) and long-acting injectable rilpivirine 900 mg (3 mL) intramuscularly at weeks 4 and 8, and every 8 weeks thereafter. The primary outcome was safety, including all adverse events, at week 24. Primary safety outcome measures were summarised as frequencies, percentages, and exact Clopper-Pearson 95% CIs in the evaluable analysis population, which included participants who were treated exclusively with the regimen and either completed all scheduled treatments or experienced severe adverse events, permanently discontinued the treatment, or died, whichever occurred first; and in the all-treated analysis population, which included all participants who received at least one dose of any study product. This study is registered with ClinicalTrials.gov (NCT3497676) and is ongoing.</p><p><strong>Findings: </strong>Between July 26, 2021, and Aug 27, 2022, 44 (80·0%) of 55 adolescents who participated in cohort 1 and 100 (87·0%) of 115 screened study-naive adolescents were enrolled in cohort 2. 74 (51·4%) participants were female and 70 (48·6%) were male. Overall, 15 (10·8% [95% CI 6·2-17·2]) of all 139 participants in the evaluable analysis population had at least one adverse event of grade 3 or above by week 24. Among 142 participants who received at least one injection, 43 (30%) experienced at least one injection site reaction (ISR). All 106 ISRs were either grade 1 (98 [92·5%]) or grade 2 (eight [7·5%]), and 97 (91·5%) resolved within 7 days. No participant experienced a drug-related serious adverse event or prematurely discontinued treatment due to a drug-related adverse event.</p><p><strong>Interpretation: </strong>Long-acting injectable cabotegravir and long-acting injectable rilpivirine, administered to adolescents at recommended adult dosages every 8 weeks, showed no unanticipa
{"title":"Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study.","authors":"Carolyn Bolton Moore, Kristin Baltrusaitis, Brookie M Best, John H Moye, Ellen Townley, Avy Violari, Barbara Heckman, Sarah Buisson, Rodica M Van Solingen-Ristea, Edmund V Capparelli, Mark A Marzinke, Elizabeth D Lowenthal, Shawn Ward, Chelsea Krotje, Ryan Milligan, Allison L Agwu, Jenny Huang, S Y Amy Cheung, Cynthia McCoig, Dwight E Yin, Gilly Roberts, Herta Crauwels, Veerle Van Eygen, Sara Zabih, Gaerolwe Masheto, Pradthana Ounchanum, Linda Aurpibul, Violet Korutaro, Aditya H Gaur","doi":"10.1016/S2352-3018(24)00344-8","DOIUrl":"https://doi.org/10.1016/S2352-3018(24)00344-8","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Long-acting cabotegravir and long-acting rilpivirine constitute a completely intramuscular antiretroviral therapy (ART) regimen for adults with HIV. We aimed to assess the safety, antiviral activity, and pharmacokinetics of oral cabotegravir and rilpivirine followed by a combination of long-acting cabotegravir and long-acting rilpivirine in virologically suppressed adolescents with HIV.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;The IMPAACT 2017/MOCHA study is a phase 1/2, multicentre, open-label, non-comparative, dose-finding trial being conducted at 18 sites across Botswana, South Africa, Thailand, Uganda, and the USA. In cohort 2 of this study, adolescents (aged 12-18 years; weight ≥35 kg) with HIV and no serious comorbidities who were receiving stable combination ART with confirmed virological suppression and had either previously enrolled in the first cohort or had not previously participated in the study were eligible for inclusion. Participants stopped their background combination ART and received oral cabotegravir 30 mg once daily and oral rilpivirine 25 mg once daily orally for 4-6 weeks, followed by long-acting injectable cabotegravir 600 mg (3 mL) and long-acting injectable rilpivirine 900 mg (3 mL) intramuscularly at weeks 4 and 8, and every 8 weeks thereafter. The primary outcome was safety, including all adverse events, at week 24. Primary safety outcome measures were summarised as frequencies, percentages, and exact Clopper-Pearson 95% CIs in the evaluable analysis population, which included participants who were treated exclusively with the regimen and either completed all scheduled treatments or experienced severe adverse events, permanently discontinued the treatment, or died, whichever occurred first; and in the all-treated analysis population, which included all participants who received at least one dose of any study product. This study is registered with ClinicalTrials.gov (NCT3497676) and is ongoing.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Findings: &lt;/strong&gt;Between July 26, 2021, and Aug 27, 2022, 44 (80·0%) of 55 adolescents who participated in cohort 1 and 100 (87·0%) of 115 screened study-naive adolescents were enrolled in cohort 2. 74 (51·4%) participants were female and 70 (48·6%) were male. Overall, 15 (10·8% [95% CI 6·2-17·2]) of all 139 participants in the evaluable analysis population had at least one adverse event of grade 3 or above by week 24. Among 142 participants who received at least one injection, 43 (30%) experienced at least one injection site reaction (ISR). All 106 ISRs were either grade 1 (98 [92·5%]) or grade 2 (eight [7·5%]), and 97 (91·5%) resolved within 7 days. No participant experienced a drug-related serious adverse event or prematurely discontinued treatment due to a drug-related adverse event.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Interpretation: &lt;/strong&gt;Long-acting injectable cabotegravir and long-acting injectable rilpivirine, administered to adolescents at recommended adult dosages every 8 weeks, showed no unanticipa","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":"12 3","pages":"e191-e200"},"PeriodicalIF":12.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143574299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trauma-informed HIV prevention for forcibly displaced adolescents and young adults.
IF 12.8 1区 医学 Q1 IMMUNOLOGY Pub Date : 2025-03-01 Epub Date: 2025-01-27 DOI: 10.1016/S2352-3018(24)00313-8
Catherine L Chantre, Trace Kershaw, Sarah R Lowe, J L Davis, Antonio Suleman, Sten H Vermund, Jennifer J Mootz

The number of people forcibly displaced due to conflict is rising rapidly each year. Previous studies have documented associations between mental ill health, HIV risk, and poor engagement with HIV care in conflict-affected populations. Most people forced to migrate are adolescents and young adults, who might already be affected by a high burden of mental ill health due to factors such as high trauma exposure during the developmental period. Adolescent girls (aged 15-19 years) and young men (aged 20-24 years) are highly vulnerable populations for HIV acquisition. Trauma and migration stress can further exacerbate the burden of mental ill health on forcibly displaced adolescents and young adults. Given the high level of vulnerability this population faces, delivery of trauma-informed HIV prevention to this group is crucial, through combined mental health and HIV interventions that are tailored to their unique developmental and socioenvironmental contexts. Trauma-informed HIV prevention is key to controlling and ending the HIV epidemic among adolescents and young adults affected by crises.

{"title":"Trauma-informed HIV prevention for forcibly displaced adolescents and young adults.","authors":"Catherine L Chantre, Trace Kershaw, Sarah R Lowe, J L Davis, Antonio Suleman, Sten H Vermund, Jennifer J Mootz","doi":"10.1016/S2352-3018(24)00313-8","DOIUrl":"10.1016/S2352-3018(24)00313-8","url":null,"abstract":"<p><p>The number of people forcibly displaced due to conflict is rising rapidly each year. Previous studies have documented associations between mental ill health, HIV risk, and poor engagement with HIV care in conflict-affected populations. Most people forced to migrate are adolescents and young adults, who might already be affected by a high burden of mental ill health due to factors such as high trauma exposure during the developmental period. Adolescent girls (aged 15-19 years) and young men (aged 20-24 years) are highly vulnerable populations for HIV acquisition. Trauma and migration stress can further exacerbate the burden of mental ill health on forcibly displaced adolescents and young adults. Given the high level of vulnerability this population faces, delivery of trauma-informed HIV prevention to this group is crucial, through combined mental health and HIV interventions that are tailored to their unique developmental and socioenvironmental contexts. Trauma-informed HIV prevention is key to controlling and ending the HIV epidemic among adolescents and young adults affected by crises.</p>","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":" ","pages":"e234-e238"},"PeriodicalIF":12.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143068885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PEPFAR halt puts millions at risk in global HIV fight.
IF 12.8 1区 医学 Q1 IMMUNOLOGY Pub Date : 2025-03-01 Epub Date: 2025-02-12 DOI: 10.1016/S2352-3018(25)00037-2
Vijay Shankar Balakrishnan
{"title":"PEPFAR halt puts millions at risk in global HIV fight.","authors":"Vijay Shankar Balakrishnan","doi":"10.1016/S2352-3018(25)00037-2","DOIUrl":"10.1016/S2352-3018(25)00037-2","url":null,"abstract":"","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":" ","pages":"e175-e177"},"PeriodicalIF":12.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143426508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Planning for the virtual elimination of HIV in Australia: a Delphi consensus.
IF 12.8 1区 医学 Q1 IMMUNOLOGY Pub Date : 2025-03-01 Epub Date: 2025-02-11 DOI: 10.1016/S2352-3018(24)00315-1
Tiffany R Phillips, Habib Taouk, Phyllis M Lau, Reuben Kiggundu, Andrew E Grulich, Aaron Cogle, Scott Harlum, Dash-Heath Paynter, Darryl O'Donnell, Jason J Ong

Australia has seen a steady decline in HIV notifications since 2013 and has one of the fastest declining rates of HIV transmission in the world. Australia is now in a globally unique position to plan for a near future of virtual elimination of HIV transmission. Through community involvement for every stage of this Delphi consensus process, we ensured the statements drafted reflect the needs of the community and highlight the gaps in the HIV response that will be essential to address if virtual elimination is to be achieved. The targeted strategies developed address how to reduce HIV transmission at every stage and facet of the HIV response (including prevention, testing, treatment, reducing HIV stigma, and enhancing the community-led response and research), resulting in a list of specific and essential priorities for the next stage of Australia's HIV response. Essential to achieving virtual elimination is the need for continued collaboration from community organisations, clinicians, researchers, and funding agencies. As Australia is one of the few countries in the world to be able to plan for HIV elimination in the near future, this Position Paper will be a useful guide for other countries as they plan for their own HIV response.

{"title":"Planning for the virtual elimination of HIV in Australia: a Delphi consensus.","authors":"Tiffany R Phillips, Habib Taouk, Phyllis M Lau, Reuben Kiggundu, Andrew E Grulich, Aaron Cogle, Scott Harlum, Dash-Heath Paynter, Darryl O'Donnell, Jason J Ong","doi":"10.1016/S2352-3018(24)00315-1","DOIUrl":"10.1016/S2352-3018(24)00315-1","url":null,"abstract":"<p><p>Australia has seen a steady decline in HIV notifications since 2013 and has one of the fastest declining rates of HIV transmission in the world. Australia is now in a globally unique position to plan for a near future of virtual elimination of HIV transmission. Through community involvement for every stage of this Delphi consensus process, we ensured the statements drafted reflect the needs of the community and highlight the gaps in the HIV response that will be essential to address if virtual elimination is to be achieved. The targeted strategies developed address how to reduce HIV transmission at every stage and facet of the HIV response (including prevention, testing, treatment, reducing HIV stigma, and enhancing the community-led response and research), resulting in a list of specific and essential priorities for the next stage of Australia's HIV response. Essential to achieving virtual elimination is the need for continued collaboration from community organisations, clinicians, researchers, and funding agencies. As Australia is one of the few countries in the world to be able to plan for HIV elimination in the near future, this Position Paper will be a useful guide for other countries as they plan for their own HIV response.</p>","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":" ","pages":"e223-e233"},"PeriodicalIF":12.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143426449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of life-course events with predictors of HIV risk behaviour and HIV acquisition in Manicaland, Zimbabwe: a longitudinal analysis of a population cohort. 津巴布韦马尼卡兰德的生命历程事件与艾滋病毒风险行为和艾滋病毒感染的预测因素之间的关系:对人口队列的纵向分析。
IF 12.8 1区 医学 Q1 IMMUNOLOGY Pub Date : 2025-03-01 Epub Date: 2025-02-14 DOI: 10.1016/S2352-3018(24)00317-5
Michael Pickles, Simon Gregson, Louisa Moorhouse, Rufurwokuda Maswera, Blessing Tsenesa, Freedom Dzamatira, Phyllis Mandizvidza, Sophie Bagnay, Tawanda Dadirai, Brian Kumbirai Moyo, Owen Mugurungi, Constance Nyamukapa, Timothy B Hallett

Background: An individual's HIV risk, and consequently their HIV prevention needs, change over time. In this study we aimed to quantify these changes, examine which life-course events were associated with them, and investigate the extent to which those life-course events were associated with HIV acquisition.

Methods: We used longitudinal data from eight rounds of a general population cohort in Manicaland province, eastern Zimbabwe, on sociodemographic and HIV risk behaviours, as well as HIV serostatus from the first seven rounds. We first visualised how HIV risk behaviours, comprised of having multiple, concurrent, non-regular, or transactional partners, condom non-use, drug use, and visiting bars, changed for individuals over time using Sankey diagrams. We then examined whether logistic regression models incorporating life-course events-namely, changes in marital or employment status, in-migration, or birth of a child-were more strongly associated with changes in HIV risk behaviour than models using only sociodemographic variables. Finally, we compared how well sociodemographic, HIV risk behaviour, and life-course events were associated with the person's risk of HIV acquisition as follows: we used logistic regression to identify which states (divided into sociodemographic, HIV risk behaviour, and life-course events) were most strongly associated with risk of HIV acquisition; based on this we use three models (corresponding to the three divisions) to identify the top 20% of individuals predicted to be at risk of acquiring HIV by each model, and computed what proportion of the actual HIV infection events occurred in that group.

Findings: Between 1998 and 2021, 21 213 individuals were interviewed at least twice, contributing a total of 34 212 participant observations. In this setting, individuals had periods of HIV risk lasting less than 3 years; only 12·3% (102 of 831) of those reporting transactional sex had also reported this in the previous round. We found that life-course events such as changes in marital status, employment status, and in-migrant status were associated with these changes in HIV risk behaviour. Using life-course events, particularly ones related to changes in marital status, 23% and 30% more HIV acquisitions were identified than using HIV risk behaviours or sociodemographic information, respectively.

Interpretation: HIV risk changes dynamically in this population, and life-course events could be a powerful way to understand changes in HIV risk behaviour and risk of HIV acquisition.

Funding: Bill and Melinda Gates Foundation, UK Medical Research Council, and Department for International Development.

{"title":"Association of life-course events with predictors of HIV risk behaviour and HIV acquisition in Manicaland, Zimbabwe: a longitudinal analysis of a population cohort.","authors":"Michael Pickles, Simon Gregson, Louisa Moorhouse, Rufurwokuda Maswera, Blessing Tsenesa, Freedom Dzamatira, Phyllis Mandizvidza, Sophie Bagnay, Tawanda Dadirai, Brian Kumbirai Moyo, Owen Mugurungi, Constance Nyamukapa, Timothy B Hallett","doi":"10.1016/S2352-3018(24)00317-5","DOIUrl":"10.1016/S2352-3018(24)00317-5","url":null,"abstract":"<p><strong>Background: </strong>An individual's HIV risk, and consequently their HIV prevention needs, change over time. In this study we aimed to quantify these changes, examine which life-course events were associated with them, and investigate the extent to which those life-course events were associated with HIV acquisition.</p><p><strong>Methods: </strong>We used longitudinal data from eight rounds of a general population cohort in Manicaland province, eastern Zimbabwe, on sociodemographic and HIV risk behaviours, as well as HIV serostatus from the first seven rounds. We first visualised how HIV risk behaviours, comprised of having multiple, concurrent, non-regular, or transactional partners, condom non-use, drug use, and visiting bars, changed for individuals over time using Sankey diagrams. We then examined whether logistic regression models incorporating life-course events-namely, changes in marital or employment status, in-migration, or birth of a child-were more strongly associated with changes in HIV risk behaviour than models using only sociodemographic variables. Finally, we compared how well sociodemographic, HIV risk behaviour, and life-course events were associated with the person's risk of HIV acquisition as follows: we used logistic regression to identify which states (divided into sociodemographic, HIV risk behaviour, and life-course events) were most strongly associated with risk of HIV acquisition; based on this we use three models (corresponding to the three divisions) to identify the top 20% of individuals predicted to be at risk of acquiring HIV by each model, and computed what proportion of the actual HIV infection events occurred in that group.</p><p><strong>Findings: </strong>Between 1998 and 2021, 21 213 individuals were interviewed at least twice, contributing a total of 34 212 participant observations. In this setting, individuals had periods of HIV risk lasting less than 3 years; only 12·3% (102 of 831) of those reporting transactional sex had also reported this in the previous round. We found that life-course events such as changes in marital status, employment status, and in-migrant status were associated with these changes in HIV risk behaviour. Using life-course events, particularly ones related to changes in marital status, 23% and 30% more HIV acquisitions were identified than using HIV risk behaviours or sociodemographic information, respectively.</p><p><strong>Interpretation: </strong>HIV risk changes dynamically in this population, and life-course events could be a powerful way to understand changes in HIV risk behaviour and risk of HIV acquisition.</p><p><strong>Funding: </strong>Bill and Melinda Gates Foundation, UK Medical Research Council, and Department for International Development.</p>","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":" ","pages":"e214-e222"},"PeriodicalIF":12.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143442465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Mexico City Policy, PEPFAR, and women's health.
IF 12.8 1区 医学 Q1 IMMUNOLOGY Pub Date : 2025-02-28 DOI: 10.1016/S2352-3018(25)00050-5
Domonique M Reed, Salome Kuchukhidze, Jeffrey W Imai-Eaton
{"title":"The Mexico City Policy, PEPFAR, and women's health.","authors":"Domonique M Reed, Salome Kuchukhidze, Jeffrey W Imai-Eaton","doi":"10.1016/S2352-3018(25)00050-5","DOIUrl":"https://doi.org/10.1016/S2352-3018(25)00050-5","url":null,"abstract":"","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":" ","pages":""},"PeriodicalIF":12.8,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143543848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
US funding cuts as a catalyst for African-led HIV solutions.
IF 12.8 1区 医学 Q1 IMMUNOLOGY Pub Date : 2025-02-28 DOI: 10.1016/S2352-3018(25)00049-9
Daniel A Adeyinka, Bukola Ologunagba, Babayemi O Olakunde
{"title":"US funding cuts as a catalyst for African-led HIV solutions.","authors":"Daniel A Adeyinka, Bukola Ologunagba, Babayemi O Olakunde","doi":"10.1016/S2352-3018(25)00049-9","DOIUrl":"https://doi.org/10.1016/S2352-3018(25)00049-9","url":null,"abstract":"","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":" ","pages":""},"PeriodicalIF":12.8,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143544025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacokinetics and safety of dolutegravir in children receiving rifampicin tuberculosis treatment in South Africa (ORCHID): a prospective cohort study.
IF 12.8 1区 医学 Q1 IMMUNOLOGY Pub Date : 2025-02-26 DOI: 10.1016/S2352-3018(24)00312-6
Anushka Naidoo, Hylke Waalewijn, Kogieleum Naidoo, Marothi Letsoalo, Gabriela Cromhout, Leora Sewnarain, Nozibusiso R Mosia, Emmanuella C Osuala, Lubbe Wiesner, Roeland E Wasmann, Paolo Denti, Kelly E Dooley, Moherndran Archary
<p><strong>Background: </strong>Data on the safety and pharmacokinetics of dolutegravir in children with HIV and tuberculosis are scarce. We aimed to determine the pharmacokinetics and safety of dolutegravir 50 mg twice daily in children receiving rifampicin, and to predict exposures for once-daily dolutegravir with rifampicin.</p><p><strong>Methods: </strong>ORCHID is an open-label, sequential, prospective cohort study in children (<18 years) weighing 20-35 kg initiated on a rifampicin-based tuberculosis regimen and dolutegravir in Durban, South Africa. We collected seven plasma samples over one dosing interval from each patient while on dolutegravir 50 mg twice daily during tuberculosis treatment and while on dolutegravir 50 mg once daily after tuberculosis treatment discontinuation. Pharmacokinetic data were analysed using population modelling in NONMEM version 7.5. The final model was used to perform Monte Carlo simulations in silico of once-daily dolutegravir dosing and time below target concentration (0·064 mg/L). Participants underwent regular clinical and safety visits. HIV viral load was measured at weeks 8, 12, 24, and 48. Primary outcomes were trough concentration (C<sub>trough</sub>), maximum concentration (C<sub>max</sub>), and area under the concentration-time curve from dose to 24 h after dose (AUC<sub>0-24</sub>) and population plasma pharmacokinetic parameters (ie, absorption rate constant, volume of distribution, and oral clearance) of dolutegravir film-coated tablet 50 mg twice daily in children with and without rifampicin, assessed in all participants with evaluable pharmacokinetic data (pharmacokinetic population). Secondary outcomes included pharmacokinetic parameters for the once-daily dolutegravir dosing option with rifampicin, simulated in the pharmacokinetic population. This study is registered at ClinicalTrials.gov, NCT04746547.</p><p><strong>Findings: </strong>Between Aug 19, 2021, and Aug 17, 2023, we enrolled and followed up 13 children, with a median weight of 23·8 kg (IQR 21·7-24·8) and median age 10 years (range 5·9-13·0). Seven were male, six female, and 13 Black. Typical dolutegravir clearance was 0·584 L/h (95% CI 0·492-0·724), with an increase in clearance of 99·1% (73·2-120) with rifampicin. Median C<sub>trough</sub> was 1·45 mg/L (coefficient of variation 68%) for participants on twice-daily dolutegravir with rifampicin and 1·24 mg/L (70%) for participants on once-daily dolutegravir without rifampicin. Median viral load and CD4 count at baseline were 2·48 log<sub>10</sub> copies per mL (IQR 1·64-4·99) and 109 cells per μL (77-385), respectively. Viral load was less than 50 copies per mL in all 13 children completing week 24 and in 12 children at week 48. Four grade 3 adverse events, no grade 4 adverse events, and one serious adverse event (ie, hospitalisation) unrelated to study drug were reported, with no treatment discontinuations or switches due to adverse events. Simulated C<sub>trough</sub> values for d
背景:有关多罗替拉韦在儿童艾滋病和结核病患者中的安全性和药代动力学的数据很少。我们旨在确定接受利福平治疗的儿童每日两次服用 50 毫克多罗替拉韦的药代动力学和安全性,并预测每日一次服用多罗替拉韦与利福平的暴露情况:ORCHID是一项开放标签、连续性、前瞻性队列研究,研究对象为所有具有可评估药代动力学数据的参与者(药代动力学人群),评估多罗替拉韦薄膜衣片50毫克、每天两次、服用利福平和不服用利福平的儿童的药代动力学参数(即吸收率常数、分布容积和口服清除率)(谷值)、最大浓度(Cmax)和服药至服药后24小时的浓度-时间曲线下面积(AUC0-24)。次要结果包括在药代动力学人群中模拟的与利福平合用的每日一次多鲁特韦给药方案的药代动力学参数。本研究已在 ClinicalTrials.gov 注册,编号为 NCT04746547:2021年8月19日至2023年8月17日期间,我们招募并随访了13名儿童,中位体重23-8公斤(IQR 21-7-24-8),中位年龄10岁(5-9-13-0)。其中 7 人为男性,6 人为女性,13 人为黑人。典型的多鲁曲韦清除率为 0-584 L/h(95% CI 0-492-0-724),使用利福平后清除率增加 99-1%(73-2-120)。每日两次服用多鲁曲韦联合利福平的患者的中位Ctrough为1-45 mg/L(变异系数为68%),每日一次服用多鲁曲韦联合利福平的患者的中位Ctrough为1-24 mg/L(变异系数为70%)。基线病毒载量和 CD4 细胞计数的中位数分别为每毫升 2-48 log10 拷贝(IQR 1-64-4-99)和每微升 109 个细胞(77-385)。在第 24 周时,所有 13 名儿童的病毒载量均低于每毫升 50 个拷贝,在第 48 周时,有 12 名儿童的病毒载量低于每毫升 50 个拷贝。报告了四例3级不良事件、无4级不良事件和一例与研究药物无关的严重不良事件(即住院),无因不良事件导致的治疗中断或转换。如果多鲁曲韦50毫克每日一次与利福平合用,儿童的模拟Ctrough值与成人相似,低于目标值(0-064毫克/升)的时间同样很短;90%的成人和儿童高于目标值或低于目标值的时间少于2小时:在体重为20-35公斤的儿童中,每日两次使用多鲁曲韦与利福平可达到治疗浓度,且耐受性良好,病毒抑制率高。模拟结果表明,应在临床研究中对体重为20-35公斤的儿童在合用利福平期间每日一次服用多罗替拉韦的情况进行调查:经费来源:美国国立卫生研究院和南非医学研究委员会。
{"title":"Pharmacokinetics and safety of dolutegravir in children receiving rifampicin tuberculosis treatment in South Africa (ORCHID): a prospective cohort study.","authors":"Anushka Naidoo, Hylke Waalewijn, Kogieleum Naidoo, Marothi Letsoalo, Gabriela Cromhout, Leora Sewnarain, Nozibusiso R Mosia, Emmanuella C Osuala, Lubbe Wiesner, Roeland E Wasmann, Paolo Denti, Kelly E Dooley, Moherndran Archary","doi":"10.1016/S2352-3018(24)00312-6","DOIUrl":"https://doi.org/10.1016/S2352-3018(24)00312-6","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Data on the safety and pharmacokinetics of dolutegravir in children with HIV and tuberculosis are scarce. We aimed to determine the pharmacokinetics and safety of dolutegravir 50 mg twice daily in children receiving rifampicin, and to predict exposures for once-daily dolutegravir with rifampicin.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;ORCHID is an open-label, sequential, prospective cohort study in children (&lt;18 years) weighing 20-35 kg initiated on a rifampicin-based tuberculosis regimen and dolutegravir in Durban, South Africa. We collected seven plasma samples over one dosing interval from each patient while on dolutegravir 50 mg twice daily during tuberculosis treatment and while on dolutegravir 50 mg once daily after tuberculosis treatment discontinuation. Pharmacokinetic data were analysed using population modelling in NONMEM version 7.5. The final model was used to perform Monte Carlo simulations in silico of once-daily dolutegravir dosing and time below target concentration (0·064 mg/L). Participants underwent regular clinical and safety visits. HIV viral load was measured at weeks 8, 12, 24, and 48. Primary outcomes were trough concentration (C&lt;sub&gt;trough&lt;/sub&gt;), maximum concentration (C&lt;sub&gt;max&lt;/sub&gt;), and area under the concentration-time curve from dose to 24 h after dose (AUC&lt;sub&gt;0-24&lt;/sub&gt;) and population plasma pharmacokinetic parameters (ie, absorption rate constant, volume of distribution, and oral clearance) of dolutegravir film-coated tablet 50 mg twice daily in children with and without rifampicin, assessed in all participants with evaluable pharmacokinetic data (pharmacokinetic population). Secondary outcomes included pharmacokinetic parameters for the once-daily dolutegravir dosing option with rifampicin, simulated in the pharmacokinetic population. This study is registered at ClinicalTrials.gov, NCT04746547.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Findings: &lt;/strong&gt;Between Aug 19, 2021, and Aug 17, 2023, we enrolled and followed up 13 children, with a median weight of 23·8 kg (IQR 21·7-24·8) and median age 10 years (range 5·9-13·0). Seven were male, six female, and 13 Black. Typical dolutegravir clearance was 0·584 L/h (95% CI 0·492-0·724), with an increase in clearance of 99·1% (73·2-120) with rifampicin. Median C&lt;sub&gt;trough&lt;/sub&gt; was 1·45 mg/L (coefficient of variation 68%) for participants on twice-daily dolutegravir with rifampicin and 1·24 mg/L (70%) for participants on once-daily dolutegravir without rifampicin. Median viral load and CD4 count at baseline were 2·48 log&lt;sub&gt;10&lt;/sub&gt; copies per mL (IQR 1·64-4·99) and 109 cells per μL (77-385), respectively. Viral load was less than 50 copies per mL in all 13 children completing week 24 and in 12 children at week 48. Four grade 3 adverse events, no grade 4 adverse events, and one serious adverse event (ie, hospitalisation) unrelated to study drug were reported, with no treatment discontinuations or switches due to adverse events. Simulated C&lt;sub&gt;trough&lt;/sub&gt; values for d","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":" ","pages":""},"PeriodicalIF":12.8,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143537888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Lancet Hiv
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1